Markus Warmuth - 03 Jan 2023 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
President & CEO, Director
Signature
/s/ Ajim Tamboli, Attorney-in-Fact
Issuer symbol
GLUE
Transactions as of
03 Jan 2023
Net transactions value
$0
Form type
4
Filing time
04 Jan 2023, 15:31:13 UTC
Previous filing
02 Mar 2022
Next filing
04 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GLUE Stock Option (Right to Buy) Award $0 +472,000 $0.000000 472,000 03 Jan 2023 Common Stock 472,000 $7.78 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.